Intellia Therapeutics to Present at March Investor Healthcare Conferences
Intellia Therapeutics to Hold Conference Call to Address Patent Interference Proceedings
CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Provide Update on CRISPR/Cas9 U.S. Patent Interference Proceedings and Grants of Corresponding Patents in the U.K.
Intellia Therapeutics to Present at Leerink Partners 6th Annual Global Healthcare Conference
Intellia Therapeutics Joins Genomics England’s Industry Consortium
CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Global Agreement on the Foundational Intellectual Property for CRISPR/Cas9 Gene Editing Technology
Intellia Therapeutics Names Graeme Bell Chief Financial Officer
Intellia Therapeutics Opens New Headquarters as Company Continues to Advance CRISPR/Cas9 Platform and Pipeline
Intellia Therapeutics Reports Financial Results for Third Quarter 2016
Intellia Therapeutics to Present at November Investor Healthcare Conferences